These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 26914976

  • 1. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
    Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, Miller K, Narla RK, Orlowski RZ, Raymon HK, Bjorklund CC, Thakurta A, Gandhi AK, Cathers BE, Chopra R, Daniel TO, Lopez-Girona A.
    Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
    [Abstract] [Full Text] [Related]

  • 2. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.
    Díaz T, Rodríguez V, Lozano E, Mena MP, Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J, Roué G, de Larrea CF.
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [Abstract] [Full Text] [Related]

  • 3. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS, Ray A, Song Y, Richardson P, Trikha M, Chauhan D, Anderson KC.
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [Abstract] [Full Text] [Related]

  • 4. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F, Baz R.
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [Abstract] [Full Text] [Related]

  • 5. Lenalidomide in multiple myeloma.
    Kim Y, Schmidt-Wolf IG.
    Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
    [Abstract] [Full Text] [Related]

  • 6. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.
    Soekojo CY, Kim K, Huang SY, Chim CS, Takezako N, Asaoku H, Kimura H, Kosugi H, Sakamoto J, Gopalakrishnan SK, Nagarajan C, Wei Y, Moorakonda R, Lee SL, Lee JJ, Yoon SS, Kim JS, Min CK, Lee JH, Durie B, Chng WJ.
    Blood Cancer J; 2019 Oct 08; 9(10):83. PubMed ID: 31594919
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L, Mistrík M, Bátorová A.
    Klin Onkol; 2014 Oct 08; 27(5):318-25. PubMed ID: 25312708
    [Abstract] [Full Text] [Related]

  • 9. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P.
    Semin Hematol; 2005 Oct 08; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pomalidomide therapy for myeloma.
    Schey S, Ramasamy K.
    Expert Opin Investig Drugs; 2011 May 08; 20(5):691-700. PubMed ID: 21413906
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
    Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P.
    Curr Cancer Drug Targets; 2010 Mar 08; 10(2):155-67. PubMed ID: 20088798
    [Abstract] [Full Text] [Related]

  • 17. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
    Hoy SM.
    Drugs; 2017 Nov 08; 77(17):1897-1908. PubMed ID: 29110190
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, Ning Y, Gandhi AK, Daniel TO, Chopra R, Klippel A, Thakurta AG.
    Blood Cancer J; 2015 Oct 02; 5(10):e354. PubMed ID: 26430725
    [Abstract] [Full Text] [Related]

  • 20. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A.
    Oncogene; 2014 Jan 16; 33(3):316-25. PubMed ID: 23318440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.